Philip Morris Gains Competitive Edge with FDA Authorization of ZYN Nicotine Pouches
Analyst Matthew Smith of Bank of America Securities maintained a Buy rating on Philip Morris (PM – Research Report), with a price target of ...
Buy Rating for Philip Morris: Strategic Positioning and FDA Approval of ZYN Pouches
Analyst Lisa Lewandowski from Bank of America Securities maintained a Buy rating on Philip Morris (PM – Research Report) and keeping the price ...
Philip Morris International Inc. (PM): A Bull Case Theory
We came across a bullish thesis on Philip Morris International Inc. (PM) on Substack by Chit Chat Stocks. In this article, we ...
Philip Morris: Shift To Smoke-Free Sparks Steady Dividend Growth
Learn how Philip Morris International plans to shift to smoke-free products by 2030 to mitigate risks, boost profits, and ...
FDA OKs sales of Zyn nicotine pouches, citing health benefits for adult smokers
Federal health officials are backing the health benefits of nicotine pouches, ruling that Philip Morris International's Zyn ...
Philip Morris International Inc. (NYSE:PM) Stock Position Boosted by Moody National Bank Trust Division
Moody National Bank Trust Division grew its stake in shares of Philip Morris International Inc. (NYSE:PM – Free Report) by ...
Zyn nicotine pouches get FDA approval
FDA authorizes Zyn nicotine pouches, citing public health benefits for adult smokers, despite concerns over flavored products ...
Brookstone Capital Management Has $3.20 Million Stake in Philip Morris International Inc. (NYSE:PM)
Brookstone Capital Management increased its stake in shares of Philip Morris International Inc. (NYSE:PM – Free Report) by ...
This Week In Cannabis: Rescheduling Delays, The DEA, Biden's Clemency, Philip Morris' New Bet And More
Philip Morris International (PMI), through its subsidiary Vectura Fertin Pharma, partnered with Avicanna AVCNF to advance cannabinoid-based medicine. The deal underscores PMI's strategic focus on ...